Cyclophosphamide anhydrous
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1959
- First approval year
- 1959
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Cyclophosphamide anhydrous
- Molecular weight
- 261.09
- Structure (SMILES)
- O=P1(N(CCCl)CCCl)NCCCO1
- anhydrous cyclophosphamide
- Anhydrous cyclophosphamide
- ciclofosfamida
- Ciclofosfamida
- Cyclophosphamide (anhydrous)
- CYCLOPHOSPHAMIDE [HSDB]
- cyclophosphamide [INN]
- Cyclophosphamide [WHO-DD]
- cyclophosphamide anhydrous
- Cyclophosphamide anhydrous
- CYCLOPHOSPHAMIDE ANHYDROUS [MI]
- cyclophosphamide anhydrous mi
- cyclophosphamide hsdb
- cyclophosphamide inn
- cyclophosphamide lyophilized
- Cyclophosphamide lyophilized
- cyclophosphamide who dd
- Cyclophosphamide, anhydrous
- nsc 26271
- NSC-26271
- CAS registry numbers
- 50-18-0
- ChEMBL ID
- CHEMBL88
- InChIKey
- CMSMOCZEIVJLDB-UHFFFAOYSA-N
- PubChem compound IDs
- 2907
- RxNorm IDs (RxCUI)
- 1545988
- FDA ingredient codes (UNII)
- 6UXW23996M
- Applicant
- DR REDDYS
- Approval date
- 30 Jul 2020
- Application number
- NDA212501
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- United States (FDA)
- Approved
- Pharmacology name
- cyclophosphamide
- Type
- Synthetic organic
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Parenteral
- Event
- acute myeloid leukaemia
- Reports
- 642
- Reporting signal score
- 1,203.71
- Event
- anaemia
- Reports
- 1,981
- Reporting signal score
- 664.035
- Event
- bone marrow failure
- Reports
- 792
- Reporting signal score
- 905.824
- Event
- cystitis haemorrhagic
- Reports
- 365
- Reporting signal score
- 794.44
- Event
- cytokine release syndrome
- Reports
- 547
- Reporting signal score
- 972.582
- Event
- cytomegalovirus infection
- Reports
- 747
- Reporting signal score
- 1,134.72
- Event
- diffuse large b-cell lymphoma recurrent
- Reports
- 298
- Reporting signal score
- 815.252
- Event
- disease progression
- Reports
- 1,291
- Reporting signal score
- 779.955
- Event
- febrile bone marrow aplasia
- Reports
- 421
- Reporting signal score
- 844.789
- Event
- febrile neutropenia
- Reports
- 5,340
- Reporting signal score
- 11,113.4
- Event
- haematotoxicity
- Reports
- 639
- Reporting signal score
- 1,158.35
- Event
- injection site pain
- Reports
- 6
- Reporting signal score
- 664.678
- Event
- leukopenia
- Reports
- 1,152
- Reporting signal score
- 925.431
- Event
- mucosal inflammation
- Reports
- 1,264
- Reporting signal score
- 1,814.19
- Event
- myelodysplastic syndrome
- Reports
- 919
- Reporting signal score
- 1,768.74
- Event
- neutropenia
- Reports
- 3,532
- Reporting signal score
- 3,503.61
- Event
- neutropenic sepsis
- Reports
- 474
- Reporting signal score
- 901.974
- Event
- pancytopenia
- Reports
- 1,245
- Reporting signal score
- 1,116.23
- Event
- pneumocystis jirovecii pneumonia
- Reports
- 469
- Reporting signal score
- 764.878
- Event
- pyrexia
- Reports
- 2,832
- Reporting signal score
- 848.245
- Event
- second primary malignancy
- Reports
- 430
- Reporting signal score
- 723.811
- Event
- sepsis
- Reports
- 1,124
- Reporting signal score
- 749.77
- Event
- thrombocytopenia
- Reports
- 1,987
- Reporting signal score
- 1,211.41
- Event
- tumour lysis syndrome
- Reports
- 405
- Reporting signal score
- 674.103
- Event
- venoocclusive liver disease
- Reports
- 388
- Reporting signal score
- 781.328
- Hydrogen bond acceptors
- 2
- Hydrogen bond donors
- 1
- Polar surface area
- 41.57
- Calculated partition coefficient (ALogP)
- 1.88
- Calculated partition coefficient (XLogP)
- 0.6
- Prodrug
- Yes
- Chirality
- Racemic
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 14
- Molecular formula
- C7H15Cl2N2O2P
- Monoisotopic mass
- 260.0248201
- Natural product
- Yes
- 68001-564
- 68001-565
- 75907-189
- 75907-190
- 75907-191
- Recorded assays
- 13,599
- Active assays
- 4,196
- Confirmatory
- Other
- Summary
- Immunosuppressive Agents
- Mutagens
- Antirheumatic Agents
- Antineoplastic Agents, Alkylating
- Myeloablative Agonists
Distribution coefficient (LogD)
- Median
- 0.63
- Mean
- 0.436667
- Minimum
- 0.05
- Maximum
- 0.63
- Unit
- unitless
- Assays
- 3
- Standard deviation
- 0.334863
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Oral bioavailability
- Median
- 74
- Mean
- 74
- Minimum
- 74
- Maximum
- 74
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (3,188)
- ......SMARTEST Trial......
- 'ADVANCE' (A Pilot Trial)
- "Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma
- "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
- 2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
- 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA
- 4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF
- 9-ING-41 in Pediatric Patients With Refractory Malignancies.
- A Blood Stem Cell Transplant for Sickle Cell Disease
- A Cancer Vaccine (CG8123) Given With and Without Cyclophosphamide for Advanced Stage Non-Small Cell Lung Cancer (NSCLC)
- A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
- A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
- A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer(FASTIL-Lung02)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer